Fascinating to see companies like Compass Pathways over on the
NASDAQ trading around half down from highs yet can still
boast a 1.23B market cap in USD. ![https://hotcopper.com.au/data/attachments/3101/3101942-8b04d81a57d768b19cb9d5421d053113.jpg](https://hotcopper.com.au/data/attachments/3101/3101942-8b04d81a57d768b19cb9d5421d053113.jpg)
Then we have stocks like
CARA Therapeutics who are also a NASDAQ listed cannabinoid biotech (admittedly a bit more advanced than IHL)
trading at multiyear highs. Frenzy imminent on the NASDAQ!
Currently boasting a MC of 1.42B USD.![https://hotcopper.com.au/data/attachments/3101/3101944-cbefa77016c4199246839d8c3fe39283.jpg](https://hotcopper.com.au/data/attachments/3101/3101944-cbefa77016c4199246839d8c3fe39283.jpg)
As explained in my old reddit post, making comparisons of IHL to these two among others and also GW Pharma, it's clear that when IHL lists on the NASDAQ we'll look disgustingly cheap. Cannot re-iterate this enough.
Our current market cap is 270M AUD, that's 208M USD. A share price at 51c, double from here would put us at around 540M MC AUD equivalent to 417M MC USD. Now looking at Compass and CARA, which we actually are similar to BOTH.
Let's triple that, and say at a share price of roughly $1.50 we are looking at a market cap of 1.2B USD.
Pretty fair. Mm? And that's indicative of us being fairly priced as peers to Compass (Psychedelics) and CARA (Cannabis Biotech) respectively. Not TOGETHER.
Now think of doubling that. $3 doesn't seem so far-fetched anymore does it? All depends on how the US market recieves us but it's pretty clear that US investors are not going to value us at 25.5c are they. Yaaaaaaaawn.